If you’re interested in (co-)moderating any of the communities created by me, you’re welcome to message me.

I also have the account @Novocirab@jlai.lu. Furthermore, I own the account @daswetter@feddit.org, which I hope to make a small bot out of in the future.

  • 70 Posts
  • 180 Comments
Joined 11 months ago
cake
Cake day: February 27th, 2025

help-circle
















  • One of the medications, atomoxetine, approved by the U.S. Food and Drug Administration (FDA) in 2002 for attention-deficit/hyperactivity disorder, increases levels of the excitatory neurotransmitter norepinephrine by blocking its reuptake (…). In sleep apnea patients, it’s known that the decline of norepinephrine during sleep contributes to a loss of tone among upper airway muscles, particularly the genioglossus. The other compound, called aroxybutynin, is a chemically tweaked form of a drug used to treat overactive bladder. It blocks certain receptors for acetylcholine, preventing this neurotransmitter from inhibiting the nerve that enervates genioglossus—effectively toning up the muscle during sleep.






  • And, most importantly, it’s about so much more than just the banners. For example:

    (1) A new GDPR loophole via “pseudonyms” or “IDs”. The Commission proposes to significantly narrow the definition of “personal data” – which would result in the GDPR not applying to many companies in various sectors. For example, sectors that currently operate via “pseudonyms” or random ID numbers, such as data brokers or the advertising industry, would not be (fully) covered anymore. This would done by adding a “subjective approach” in the text of the GDPR.

    Instead of having an objective definition of personal data (e.g. data that is linked to a directly or indirectly identifiable person), a subjective definition would mean that if a specific company claims that it cannot (yet) or does not aim to (currently) identify a person, the GDPR ceases to apply. Such a case-by-case decision is inherently more complex and everything but a “simplification”. It also means that data may be “personal” or not depending on the internal thinking of a company, or given the circumstances that they have at a current point. This can also make cooperation between companies more complex as some would fall under the GDPR and others not.

    (2) Pulling personal data from your device? So far, Article 5(3) ePrivacy has protected users against remote access of data stored on “terminal equipment”, such as PCs or smartphones. This is based on the right to protection of communications under Article 7 of the Charter of Fundamental Rights of the EU and made sure that companies cannot “remotely search” devices.

    The Commission now adds “white listed” processing operations for the access to terminal equipment, that would include “aggregated statistics” and “security purposes”. While the general direction of changes is understandable, the wording is extremely permissive and would also allow excessive “searches” on user devices for (tiny) security purposes.

    (3) AI Training of Meta or Google with EU’s Personal Data? When Meta or LinkedIn started using social media data, it was widely unpopular. In a recent study for example only 7% of Germans say that they want Meta to use their personal data to train AI. Nevertheless, the Commission now wants to allow the use of highly personal data (like the content of 15+ years of a social media profile) for AI training by Big Tech.